Curtana's Latest News

February 5, 2026

Curtana Pharmaceuticals Announces New Data Confirming CT-179 Effectively Crosses Blood-Brain Barrier and Synergizes with Radiation in Pediatric Brain Cancers. Austin, TX – February 5, 2026 – Curtana Pharmaceuticals, a clinical-stage biotechnology company focused on improving outcomes for brain cancer patients, today announced the publication of a new study in the International Journal of Molecular Sciences…

February 2, 2026

Preclinical Study Reveals that CT-179 Remodels the Tumor Microenvironment – Turning “Cold” Tumors “Hot” – and Significantly Enhancing the Efficacy of Immune Checkpoint Inhibitors. Austin, TX – February 2, 2026 – Curtana Pharmaceuticals, a clinical-stage biotechnology company focused on improving outcomes for brain cancer patients, today announced the publication of a pivotal new study in…

January 14, 2026

February 5, 2025

A world-leading research collaboration between QIMR Berghofer and Emory University has shown that a potential new targeted therapy for childhood brain cancer is effective in infiltrating and killing tumour cells in preclinical models.

February 4, 2025

Curtana Pharmaceuticals Announces Breakthrough in Pediatric Brain Cancer Treatment with Dual Studies Published in Nature Communications

July 15, 2021

Curtana Pharmaceuticals, a privately-held, preclinical stage biopharmaceutical company, today announced that it has signed an agreement with Catalent to support tablet formulation and manufacturing of Curtana’s CT-179, a drug therapy for the treatment of glioblastoma (GBM), medulloblastoma (MB), and other brain cancers.

June 15, 2021

Data Presented in Oral Presentation at the SNO 6Biennial Pediatric Neuro-Oncology Research Conference AUSTIN, TX — June 15, 2021 —Curtana Pharmaceuticals, a privately-held, preclinical stage biopharmaceutical company, today announced that an abstract published in Neuro-Oncology earlier this month shows that CT-179, a first-in-class OLIG2 inhibitor, significantly prolonged event-free survival in an animal model of medulloblastoma…

October 6, 2020

AUSTIN, TX — October 6, 2020 — Curtana Pharmaceuticals, a privately-held, preclinical stage biopharmaceutical company, today announced that the Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) designation to CT-179, the company’s lead Olig2 inhibitor, for the treatment of medulloblastoma (MB). With the RPD designation, Curtana Pharmaceuticals may be eligible for a…

May 21, 2020

August 22, 2017

AUSTIN, TX — August 22, 2017 — Curtana Pharmaceuticals, a privately-held, preclinical-stage biopharmaceutical company, today announced that it has completed a pre-investigational new drug (IND) meeting with the U.S. Food and Drug Administration (FDA). The purpose of the meeting was to discuss the proposed clinical development program for treating newly diagnosed adult glioblastoma (GBM) patients…

August 15, 2017

AUSTIN, TX — August 15, 2017 — Curtana Pharmaceuticals, a privately-held, preclinical stage biopharmaceutical company, today announced that the Food and Drug Administration (FDA) has granted orphan drug designation to CT-179, the company’s lead Olig2 inhibitor for the treatment of gliomas, including glioblastoma (GBM) in adults and pediatric high grade glioma in children. Glioblastoma is…

February 15, 2017